Theory Paper IIIDrNB Cardiology – Theory Notes
CLINICAL SCENARIOS FOR MECHANICAL CIRCULATORY SUPPORT (MCS)
ITHE INTERMACS AND SCAI SHOCK CLASSIFICATIONS (THE TRIAGE GOLD STANDARDS)
- The INTERMACS 7-Profile Classification (For Advanced NYHA Class IIIb–IV Heart Failure): Stratifies advanced heart failure urgency and guides the selection between Temporary (Short-Term) MCS versus Durable (Long-Term) Left Ventricular Assist Devices (LVAD):
| INTERMACS Profile | Clinical Shorthand (“Catchphrase”) | Hemodynamic & Clinical Definition | Recommended MCS / Timeline |
|---|---|---|---|
| Profile 1 | “Critical Cardiogenic Shock (Crash and Burn)” | Life-threatening hypotension despite rapidly escalating inotropes/vasopressors and critical organ hypoperfusion (worsening acidosis/lactate, anuria; corresponds to SCAI Stage D/E) | Immediate Temporary MCS (Impella, VA-ECMO, or ECPELLA) within minutes to hours (do not implant durable LVAD directly in Profile 1 due to high mortality) |
| Profile 2 | “Progressive Decline (Sliding on Inotropes)” | Dependent on continuous IV inotropes with deteriorating renal function, hepatic congestion, nutrition, or volume status | Definitive intervention (Durable LVAD or Urgent Transplant) within a few days |
| Profile 3 | “Stable but Inotrope-Dependent” | Hemodynamically stable on mild-to-moderate IV inotropes (in hospital or home), but repeated weaning attempts fail due to hypotension, symptoms, or rising creatinine | Elective Durable LVAD (HeartMate 3) or Transplant within a few weeks (Ideal Durable LVAD Window) |
| Profile 4 | “Resting Symptoms at Home on Oral Therapy” | Ambulatory on oral therapy but experiences daily resting/minimal-exertion congestion and “frequent-flier” ER/hospital readmissions | Evaluate for Durable LVAD or Transplant within weeks to a few months |
| Profile 5 | “Exertion Intolerant (Housebound)” | Comfortable at rest, unable to engage in any activity, living predominantly within the house/bed-to-chair | Optimize GDMT/CRT; serial CPET and transplant/LVAD evaluation |
| Profile 6 | “Exertion Limited (Walking Wounded)” | Minor-exertion fatigue within a few blocks, able to leave the house briefly | Medical optimization (Durable LVAD generally not indicated) |
| Profile 7 | “Advanced NYHA Class III” | Clinically stable with reasonable activity level, history of recent decompensation | Medical management |
IISCENARIO 1: ACUTE CARDIOGENIC SHOCK — “BRIDGE TO RECOVERY” OR “BRIDGE TO DECISION”
- Clinical Settings: AMI-Related Cardiogenic Shock (AMI-CS), Fulminant Myocarditis (lymphocytic or giant cell), Peripartum Cardiomyopathy, Takotsubo Syndrome, or Post-Cardiotomy Shock.
- Guideline Stance and Landmark Trial Shifts (ESC 2021/2023 HF & ACC/AHA 2022):
- Downgrading of Routine IABP in AMI-CS (Class III — No Benefit): Based on the IABP-SHOCK II Trial (NEJM 2012; n = 600), routine Intra-Aortic Balloon Pump (IABP) placement in AMI-CS does not reduce 30-day, 1-year, or 6-year mortality; in contemporary ESC guidelines, IABP is reserved specifically for mechanical complications of AMI (Class IIa for acute mitral regurgitation or ventricular septal rupture) or non-ischemic ADHF bridge.
- Microaxial Flow Pump (Impella CP) Survival Breakthrough — The DanGer Shock Trial (NEJM 2024): Randomized 355 patients with STEMI complicated by Cardiogenic Shock (SCAI Stage C/D/E, arterial lactate >=2.5 mmol/L, LVEF <45%, excluding comatose post-arrest patients) to Impella CP + Standard Care versus Standard Care Alone. Impella CP significantly reduced 180-day all-cause mortality from 58.5 percent to 45.8 percent (Absolute Risk Reduction 12.7%; HR 0.74; p = 0.04; NNT = 8)—providing the first randomized trial proof in 25 years (since the 1999 SHOCK Trial) that an active temporary MCS device reduces mortality in AMI-CS (despite higher rates of limb ischemia and renal replacement therapy).
- Routine Early VA-ECMO in AMI-CS — The ECLS-SHOCK Trial (NEJM 2023): Randomized 420 patients with AMI-CS (78% of whom had resuscitated cardiac arrest) to early routine VA-ECMO versus medical therapy alone; routine VA-ECMO did NOT reduce 30-day mortality (47.8% vs. 49.0%; p = 0.81) and doubled major bleeding and peripheral vascular complications. Consequently, VA-ECMO is reserved for refractory biventricular arrest (ECPR), severe hypoxemic respiratory failure, or INTERMACS 1 crash-and-burn as a “Bridge to Decision” (often requiring LV venting via Impella [“ECPELLA”] or IABP because retrograde aortic ECMO flow increases LV afterload and causes pulmonary edema/aortic root thrombosis).
IIISCENARIO 2: HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION (“PROTECTED PCI”)
- Clinical Setting: Complex multivessel, unprotected Left Main, or last-remaining-vessel PCI (often requiring rotational atherectomy/IVL) in patients with severe LV systolic dysfunction (LVEF <=30 to 35%) who are turned down for CABG.
- Evidence (BCIS-1 and PROTECT II Trials): In PROTECT II (Circulation 2012), prophylactic Impella 2.5 (providing 2.5 L/min active forward flow and direct LV unloading) vs. IABP in complex PCI with LVEF <=35% showed similar 30-day intent-to-treat MACE, but significantly lower 90-day MACE in the per-protocol analysis (40.0% vs. 51.0%; p = 0.023) by preventing intraprocedural hemodynamic collapse during prolonged balloon/atherectomy runs (ongoing PROTECT IV RCT is testing Impella CP/5.5 in CHIP).
IVSCENARIOS 3, 4 & 5: DURABLE LEFT VENTRICULAR ASSIST DEVICES (LVAD — HEARTMATE 3)
- Abandonment of Historical “BTT vs. DT” Silos (MOMENTUM 3 Trial Paradigm): While durable LVADs are implanted clinically as Bridge to Transplant (BTT) (for listed candidates deteriorating at INTERMACS 2–3), Bridge to Candidacy (BTC) (to reverse “fixed” secondary pulmonary hypertension [PVR >5 WU] or cardiorenal dysfunction so the patient can become transplant-eligible), or Destination Therapy (DT) (lifelong support in transplant-ineligible patients aged >70 years or with recent malignancy/obesity), the MOMENTUM 3 Trial proved that clinical outcomes are identical across BTT, BTC, and DT categories.
- Eligibility Criteria for Durable LVAD (ESC 2021 / AHA-ACC 2022 Class I for Inotrope-Dependent; Class IIa for Ambulatory Advanced HF): Persistent NYHA Class IV symptoms for >=60–90 days despite optimal GDMT/CRT, LVEF <25%, Peak VO2 <12 mL/kg/min, and at least one of: inotrope/temporary MCS dependency (INTERMACS 2–3), >=3 HF hospitalizations in 12 months, or progressive end-organ renal/hepatic dysfunction—in the absence of severe irreversible Right Ventricular Failure.
- Landmark Trial — MOMENTUM 3 (NEJM 2019 & 5-Year Extended Results, Mehra et al., JAMA 2022):
- Design: Randomized 1,028 advanced HFrEF patients to the HeartMate 3 (fully magnetically levitated [Full MagLev] centrifugal-flow pump with wide blood-flow gaps, frictionless rotor, and intrinsic artificial pulse every 2 seconds) versus the HeartMate II (mechanical-bearing axial-flow pump).
- Results: HeartMate 3 significantly improved the 2-year primary composite endpoint (survival free of disabling stroke or reoperation to replace/remove a malfunctioning pump: 76.9% vs. 64.8% in the final report), virtually eliminated pump thrombosis (1.4% vs. 13.9%), halved stroke rates, and achieved a 5-year overall survival of 58.4 percent (approaching the survival of marginal heart transplant recipients).
- ARIES-HM3 Trial (JAMA 2023 — Aspirin-Free Antithrombotic Regimen): Demonstrated that in patients with a HeartMate 3 LVAD, eliminating Aspirin and treating with Warfarin (INR 2.0–3.0) alone was non-inferior for thromboembolism (zero pump thrombosis) while reducing non-surgical major bleeding (primarily GI bleeding from acquired von Willebrand syndrome and arteriovenous malformations) by 34 percent.
| MCS Device | Cannulation & Pump Mechanism | Max Flow (L/min) | Direct LV Unloading (Reduces LVEDP & MVO2)? | Primary Clinical Role |
|---|---|---|---|---|
| IABP | Femoral/axillary descending aorta; counterpulsation | 0.5 L/min | Mild (reduces afterload) | Mechanical AMI complications (acute MR/VSD — Class IIa); neutral in routine AMI-CS (IABP-SHOCK II) |
| Impella CP / 5.5 | Retrograde transaortic (LV to Ascending Aorta); microaxial pump | 3.5–4.3 L/min (CP); 5.5–6.0 L/min (5.5) | Profound Direct LV Unloading | AMI-CS (DanGer Shock: 12.7% mortality ARR), Protected PCI (PROTECT II), or ECPELLA LV vent |
| TandemHeart | Transseptal (Left Atrium to Iliofemoral Artery); centrifugal | 4.0–5.0 L/min | Indirect (unloads LA; usable with LV thrombus or mechanical aortic valve) | Severe LV shock when LV thrombus or mechanical AVR precludes Impella |
| VA-ECMO | Right Atrium/Femoral Vein to Femoral Artery + oxygenator | 4.0–7.0 L/min | NO (Increases LV Afterload -> requires Impella/IABP vent) | Biventricular crash-and-burn (INTERMACS 1), ECPR arrest, or RV failure with hypoxia |
| HeartMate 3 LVAD | Surgical LV Apex to Ascending Aorta; Full MagLev centrifugal | Up to 10 L/min | Complete Durable LV Unloading | BTT, BTC, & Destination Therapy in INTERMACS 2–4 (MOMENTUM 3 & ARIES-HM3) |
VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- Resource-Stratified Temporary MCS Selection: Because percutaneous Impella catheters and durable HeartMate 3 LVADs carry prohibitive out-of-pocket costs in India, IABP + Inotropes (in pre-shock / SCAI Stage B–C or acute mechanical complications) and peripheral VA-ECMO (managed by in-house cardiac surgery perfusion teams at a fraction of the disposable catheter cost of Impella) serve as the primary workhorses for acute Bridge-to-Recovery (e.g., fulminant viral/dengue myocarditis, aluminum phosphide poisoning, or post-cardiotomy shock) and Bridge-to-Transplant.
Key references
- Møller JE, Engstrøm T, Jensen LO, et al. (DanGer Shock Investigators): Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock, New England Journal of Medicine, 2024.
- Thiele H, Zeymer U, Akin I, et al. (ECLS-SHOCK Investigators): Extracorporeal Life Support in Infarct-Related Cardiogenic Shock, New England Journal of Medicine, 2023.
- Mehra MR, Uriel N, Naka Y, et al. & Mehra MR, Goldstein DJ, et al. (MOMENTUM 3 Investigators): A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report (NEJM 2019) & Five-Year Outcomes (JAMA 2022).
- Mehra MR, Netuka I, Uriel N, et al. (ARIES-HM3 Investigators): Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial, JAMA, 2023.
meritmedscript.comDr. Sidhartha Mullapudi
